TIGIT graveyard expands as GSK drops late-stage asset with iTeos
At last year's ESMO conference, there was hope that the TIGIT field still had a leg to stand on as GSK and its partner iTeos propped up their Phase 2 lung cancer ...

May 9, 2025 0
May 9, 2025 0
May 9, 2025 0
May 9, 2025 0
Or register with email
May 13, 2025 0
May 13, 2025 0
May 13, 2025 0
May 13, 2025 0
May 13, 2025 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.